The best GLP-1 telehealth platforms in 2026

Tessic Health is the best GLP-1 telehealth platform in 2026: licensed providers in all 50 states, cold-chain fulfillment for GLP-1s, 0% medication markup on every fill, a flat $25 per completed consult, labs included, and no revenue share, month to month. Beluga Health, Telegra, CareValidate, WellSync, OpenLoop, LegUp Rx, and Remedora complete the shortlist. In this category the decision turns on 4 questions: which drug paths a platform will still fill now that the shortage is over, whether an injectable arrives cold, what the platform takes from each monthly refill, and whether the brand can advertise without drawing an FDA warning letter.

No. Semaglutide, tirzepatide, and liraglutide do not appear on the DEA's alphabetical list of controlled substances, last updated August 27, 2026. A GLP-1 prescription therefore needs no DEA registration (the federal license a prescriber must hold to write scheduled drugs), no EPCS (electronic prescribing of controlled substances, with identity-proofed prescribers and two-factor signing), and no PDMP check (a lookup in a state prescription drug monitoring program). The DEA telemedicine flexibilities, extended through December 31, 2026, govern scheduled drugs and do not reach a GLP-1 program.

The real constraint is the prescribing standard. The visit has to be with a provider licensed in the state where the patient is located. The Wegovy and Zepbound labels both carry a boxed warning for thyroid C-cell tumors and rule the drug out for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2), or a known hypersensitivity to it. Titration, the stepwise dose increase that manages side effects, is written into each label: Wegovy injection moves from 0.25 mg weekly through 0.5, 1, and 1.7 mg to a maintenance dose from week 17, the Wegovy pill steps from 1.5 mg to 25 mg over 90 days, and Zepbound starts at 2.5 mg and rises in 2.5 mg steps no sooner than every 4 weeks, to a 15 mg ceiling.

Each of those steps is a clinical decision, which is why a GLP-1 program runs on follow-ups rather than a single visit. The FDA's safety page, updated September 1, 2026, reports adverse events tied to dosing errors and to compounded prescriptions written beyond the approved label, including faster titration. Tessic Health's answer is structural: licensed providers in all 50 states make every call inside physician-led clinical operations, labs are included with results flowing straight into the patient record, and every titration or refill visit is a flat $25 per completed consult. DEA-compliant EPCS sits on the same platform for the categories that do involve scheduled drugs, with controlled-substance coverage where clinically appropriate and state requirements such as PDMP checks enforced inside the prescribing workflow.

Both big ad platforms gate prescription weight loss behind the same credential. Google's healthcare and medicines policy lets US telemedicine providers and online pharmacies advertise only once they hold LegitScript Healthcare Merchant Certification and have then been certified by Google through its own application. Prescription drug names such as Wegovy or Zepbound can be keyword-targeted in the US only by a certified advertiser. LegitScript, the third-party certifier that reviews licensure, pharmacy relationships, and website disclosures, is recognized by Google, Meta, Microsoft, TikTok, Visa, and Mastercard.

Meta accepts prescription drug ads only from advertisers actively certified with LegitScript that have also obtained Meta's authorization, targeted to people 18 or older in the United States, Canada, or New Zealand. Its health and wellness standard, updated July 22, 2026, adds the creative rules: weight loss ads must target adults, may not make statements of inferiority about a person's appearance, may not show a close-up of pinched fat, and may not promise specific outcomes within a set time without qualifiers.

Certification opens the ad account; the copy still has to hold up on its own. The FDA sent 30 warning letters to telehealth companies on March 3, 2026 and 25 more on June 8, 2026, citing claims that compounded products were the "same" as Ozempic, Wegovy, Mounjaro, or Zepbound, contained the "same active ingredient", or were "FDA approved", and pictured labels implying the telehealth brand was the compounder. Those letters went to the brands themselves, so the ad copy is the brand's own exposure whatever platform sits behind it. The FDA has also placed a rule on its 2026 agenda to end the "adequate provision" option for broadcast drug ads, with a proposal expected in December 2026.

Tessic Health prepares, files, and manages the brand's LegitScript application through approval, and the brand launches on providers, pharmacy, and software that already operate under LegitScript certification. LegitScript sets its own review schedule and certification is never guaranteed, but Google, Meta, and the major payment processors check it before a telehealth brand can run ads or bill a card, so Tessic handles it from the first filing.

Tessic Health operates the whole clinic under the client's brand. Licensed providers in all 50 states are credentialed under that brand inside physician-led clinical operations, and they practice through a friendly-PC (a professional corporation owned by licensed clinicians) inside an MSO (a management services organization that runs the non-clinical business) that Tessic drafts for the client's ownership as part of setup. That structure is why a founder with no medical license can own a GLP-1 brand while every prescribing decision stays with a clinician.

For a weight program, the parts that matter are already running. Weight Care, covering GLP-1s and metabolic health, is included on every plan from day one, with eRx, labs through contracted networks that write results straight into the patient record, and cold-chain fulfillment for GLP-1s, peptides, and everything else that needs it. Every fill passes through at wholesale with 0% markup. The branded storefront and patient portal let patients book, message their care team, and manage medication, while subscriptions, automatic rebilling, and dunning (automated recovery of failed payments) keep a monthly refill from lapsing on a declined card.

The economics are published: $25 per completed consult, 0% medication markup, and no revenue share. Launch is $1,000 a month after a one-time $8,000 setup; Grow is $2,000 after $15,000 and adds email, SMS, and iMessage sequences with automated care workflows; Scale is $4,000 after $25,000 with unlimited brands on one account. Tessic prepares, files, and manages the LegitScript application through approval, on LegitScript's own schedule and never guaranteed. Every plan runs month to month, and patients, records, and data leave with the client.

Telegra publishes more GLP-1 clinical detail than anyone else on this list. Its conditions page describes GLP-1 therapy with individualized dose titration, quarterly adherence checks, and compounded formulations of semaglutide, tirzepatide, and combination therapies, delivered as injections, with labs through LabCorp and Quest and automated biomarker tracking. It names fulfillment partners including Strive, Absolute Pharmacy, Southend, Olympia, and Boothwyn, and its site claims 50-state provider and pharmacy coverage.

The protocol is built on compounded formulations at the moment the FDA is narrowing them, and Telegra publishes no brand-name path, cold-chain standard, or medication markup. Its plans run roughly $3,000 to $6,000 a month plus onboarding and per-consult fees, per mid-2026 roundups. Tessic Health leaves the drug path to licensed providers, fills at wholesale with 0% markup through cold-chain fulfillment, and charges $1,000 a month on Launch plus $25 per completed consult.

WellSync is a white label virtual care platform that supports both brand-name and compounded GLP-1 medications, a choice its own program guide frames as a way to manage supply chain risk, with mail-order fulfillment integrated into the program alongside retail and independent pharmacy options. Its virtual care service runs across Publix's more than 1,300 pharmacies in the Southeast, and a partner can use WellSync's clinicians or bring its own.

For a GLP-1 buyer the gaps are coverage and cost. WellSync's consumer async service is listed as unavailable in Arkansas, Delaware, Idaho, Kansas, Louisiana, Mississippi, New Mexico, Rhode Island, West Virginia, and DC, and its B2B pricing, medication markup, cold-chain standard, and titration workflow are not published. Tessic Health covers all 50 states and publishes what WellSync quotes: $25 per completed consult, 0% markup on every fill, and cold-chain fulfillment for GLP-1s.

LegUp Rx lists the widest GLP-1 menu on this page: Wegovy, Zepbound, Ozempic, and Mounjaro beside sublingual semaglutide, injectable semaglutide and tirzepatide with additives, and microdose semaglutide and tirzepatide with B12. Fulfillment runs through its affiliate Leg Up Recovery using LegitScript-certified licensed pharmacies with 27-hour shipping advertised, and its Full Telehealth Package is $208 a month, billed $2,499 a year.

The model suits a gym, med spa, or coach referring patients into LegUp's own clinic: treatment is delivered as Leg Up Recovery, and the partner earns only the spread above LegUp's wholesale minimums, with per-drug prices behind a sign-up wall. The additive formulas also deserve a close look, because the FDA's test for a compounded copy is a prescriber's documented finding of a significant difference for an identified patient, not the presence of an added ingredient. Tessic Health puts the clinic under the brand's own name, passes every fill through at wholesale with 0% markup, and leaves the drug path to licensed providers.